Document Detail


Effects of latanoprost and timolol-XE on hydrodynamics in the normal eye.
MedLine Citation:
PMID:  11004288     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To compare the effects of latanoprost and timolol-XE on ocular pressure and perfusion in healthy adults, with respect to episcleral venous pressure.
METHODS: A double-masked, placebo-controlled crossover study of weeklong bedtime treatment with one drop of drug, with placebo contralaterally, followed by a 3-week washout and alternate-drug/contralateral-placebo repeat. Intraocular pressure was measured by applanation and by pneumotonometry, providing pulsatile ocular circulatory estimates. Measurements of episcleral venous pressure were obtained (Friberg method).
RESULTS: Twenty subjects participated (five men, 15 women; mean age, 39 years (range, 21 to 55 years); mean baseline intraocular pressure, 13.4 mm Hg). A greater decrease in intraocular pressure was seen among these subjects the morning after initiating treatment with latanoprost (-2.0 mm Hg; P <.0001) than with timolol-XE (-0.9 mm Hg; P =.051) (latanoprost versus timolol DeltaP =.008). This ocular hypotensive effect remained significant that evening with latanoprost (-3.2 mm Hg; P <.0001) but not with timolol XE (-1.0 mm Hg; P =.2). By the morning of day 8, mean intraocular pressure remained 3.2 mm Hg below baseline with latanoprost and 2.3 mm Hg below baseline with timolol-XE (P <.0001 for both drugs). Neither drug altered episcleral venous pressure. Among a subgroup of nine subjects with comparable intraocular pressure reductions with the two drugs, latanoprost treatment was associated with a 16.7% increase in mean pulsatile ocular blood flow (P =.04) through the weeklong treatment interval, consistently higher than during timolol-XE treatment of the same subjects.
CONCLUSION: Latanoprost caused an overnight decrease in intraocular pressure in normotensive normal eyes, and both drugs significantly reduced intraocular pressure within 1 week. Intraocular pressure remained higher than episcleral venous pressure throughout treatment with both drugs. Latanoprost was associated with enhanced pulsatile ocular perfusion not seen with timolol-XE treatment.
Authors:
W E Sponsel; J Mensah; J W Kiel; A Remky; Y Trigo; W Baca; T Friberg
Related Documents :
8739678 - A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients...
17519068 - A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fix...
11384568 - Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary ...
12472448 - Normal tension glaucoma: diagnostic features and comparisons with primary open angle gl...
6591908 - The effect of dihydroergotamine on venous distensibility and blood pressure in idiopath...
1937678 - Functional derangements in the regulation of aldosterone secretion in hypertension.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of ophthalmology     Volume:  130     ISSN:  0002-9394     ISO Abbreviation:  Am. J. Ophthalmol.     Publication Date:  2000 Aug 
Date Detail:
Created Date:  2000-10-26     Completed Date:  2000-11-01     Revised Date:  2013-01-31    
Medline Journal Info:
Nlm Unique ID:  0370500     Medline TA:  Am J Ophthalmol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  151-9     Citation Subset:  AIM; IM    
Affiliation:
Department of Ophthalmology, University of Texas Health Science Center, San Antonio, Texas 78284-6230, USA. sponsel@earthlink.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / pharmacology*
Adult
Antihypertensive Agents / pharmacology*
Circadian Rhythm / drug effects
Cross-Over Studies
Double-Blind Method
Female
Gels
Humans
Intraocular Pressure / drug effects*
Male
Middle Aged
Ophthalmic Solutions / pharmacology
Prostaglandins F, Synthetic / pharmacology*
Pulsatile Flow / drug effects
Sclera / blood supply
Timolol / pharmacology*
Tonometry, Ocular
Venous Pressure / drug effects*
Grant Support
ID/Acronym/Agency:
R01 EY009702/EY/NEI NIH HHS
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Gels; 0/Ophthalmic Solutions; 0/Prostaglandins F, Synthetic; 130209-82-4/latanoprost; 26839-75-8/Timolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term intraocular pressure-lowering efficacy and safety of timolol maleate gel-forming solution ...
Next Document:  Learning effect, short-term fluctuation, and long-term fluctuation in frequency doubling technique.